This site is intended for U.S. Healthcare Professionals only.

ALBUKED 5 [Albumin (Human), USP]1
• 0.004 M sodium caprylate • 0.004 M acetyltryptophan
|
ALBUKED 25 [Albumin (Human), USP]2
• 0.02 M sodium caprylate • 0.02 M acetyltryptophan
|
| Product |
Volume |
Grams Albumin |
Vial Dimensions |
NDC Number |
|
ALBUKEDTM 5 |
250 mL |
12.5 g |
32mm x 143mm x 64.6mm (Current) 28mm x 149.2mm x 64mm (Additional) |
76125-790-25 |
|
ALBUKEDTM 25 |
50 mL |
12.5 g |
32mm x 70mm x 46mm (Current) 20mm x 74.5mm x 43.3mm (Additional) |
76125-792-25 |
|
ALBUKEDTM 25 |
100 mL |
25.0 g |
32mm x 105mm x 52mm (Current) 20mm x 94.5mm x 51.6mm (Coming March 2023) |
76125-792-10 |
Note: Vial sizes do not impact product formulation, indication, or administration.
References: 1. AlbukedTM 5 [prescribing information]. Fort Lee, NJ. Kedrion Biopharma Inc. 2018; 2. AlbukedTM 25 [prescribing information]. Fort Lee, NJ. Kedrion Biopharma Inc. 2018.

ALBUKED (Albumin [Human], USP) is available in two concentrations, 5% (ALBUKED 5) and 25% (ALBUKED 25), for the following indications: emergency treatment of hypovolemic shock, burn therapy, hypoproteinemia with or without edema, adult respiratory distress syndrome (ARDS), cardiopulmonary bypass, acute liver failure, sequestration of protein rich fluids. See Indications for additional information.
Situations in Which ALBUKED is NOT Warranted: In chronic nephrosis, infused albumin is promptly excreted by the kidneys with no relief of the chronic edema or effect on the underlying renal lesion. It is of occasional use in the rapid “priming” diuresis of nephrosis. Similarly, in hypoproteinemic states associated with chronic cirrhosis, malabsorption, protein losing enteropathies, pancreatic insufficiency, and undernutrition, the infusion of albumin as a source of protein nutrition is not justified.